CAR-T therapy Follow-Up study shows no new safety surprises

NCT ID NCT04488354

First seen Apr 22, 2026 · Last updated May 02, 2026 · Updated 2 times

Summary

This study followed 16 people with certain blood cancers who had already received a special treatment called CLBR001 CAR-T cells. The goal was to see if any new or long-term side effects appeared over time. Researchers also checked how well the cancer was controlled. The study did not test a new treatment but instead gathered important safety information for future use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA (FL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope National Medical Center

    Duarte, California, 91010, United States

  • Masonic Cancer Center, University of Minnesota

    Minneapolis, Minnesota, 55455, United States

  • Sarah Cannon Research Institute - Tennessee Oncology

    Nashville, Tennessee, 37203, United States

  • Sarah Cannon Research Institute - Texas Transplant Institute

    San Antonio, Texas, 78229, United States

  • University of California at San Diego

    San Diego, California, 92093, United States

  • University of Chicago

    Chicago, Illinois, 60637, United States

  • Wake Forest Baptist Health

    Winston-Salem, North Carolina, 27157, United States

  • Weill Cornell Medical College - New York Presbyterian Hospital

    New York, New York, 10065, United States

Conditions

Explore the condition pages connected to this study.